Literature DB >> 26910802

Late presentations of congenital myasthenic syndromes: How many do we miss?

Nidhi Garg1, Con Yiannikas2, Todd A Hardy1, Katsiaryna Belaya3, Jonathan Cheung3, David Beeson3, Stephen W Reddel4.   

Abstract

INTRODUCTION: Congenital myasthenic syndromes (CMS) usually present neonatally or in early childhood. When they present later, they may be mistaken for seronegative autoimmune myasthenia, and unnecessary immunosuppressive treatment may be administered.
METHODS: Patients who met criteria for seronegative generalized myasthenia without congenital or early childhood onset, but with an affected sibling were tested for CMS associated genes using exome and Sanger sequencing.
RESULTS: Four sibling pairs from nonconsanguineous families were identified. Three had mutations in the RAPSN gene, and 1 had a mutation in CHRNA1. One sibling of a pair with symptoms of fatigue but no convincing features of neuromuscular dysfunction tested negative on genetic studies. The definite CMS cases comprised 7 of 25 seronegative patients with definite generalized myasthenia in the clinic, and over half had been treated for autoimmune myasthenia.
CONCLUSIONS: CMS is probably underdiagnosed in seronegative myasthenic disorders and should be considered in the differential diagnosis. Muscle Nerve 54: 721-727, 2016.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  CHRNA1; RAPSN; congenital myasthenic syndrome; genetics; myasthenia gravis; seronegative

Mesh:

Year:  2016        PMID: 26910802     DOI: 10.1002/mus.25085

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  5 in total

1.  Novel compound heterozygous variants in the GFPT1 gene leading to rare limb-girdle congenital myasthenic syndrome with rimmed vacuoles.

Authors:  Yanyan Ma; Ting Xiong; Guohua Lei; Jiaqi Ding; Rui Yang; Zunbo Li; Jun Guo; Dingguo Shen
Journal:  Neurol Sci       Date:  2021-01-13       Impact factor: 3.307

2.  Congenital myasthenic syndromes in Turkey: Clinical clues and prognosis with long term follow-up.

Authors:  Hacer Durmus; Xin-Ming Shen; Piraye Serdaroglu-Oflazer; Bulent Kara; Yesim Parman-Gulsen; Coskun Ozdemir; Joan Brengman; Feza Deymeer; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2017-11-28       Impact factor: 4.296

3.  Congenital myasthenic syndromes in adult neurology clinic: A long road to diagnosis and therapy.

Authors:  Justin C Kao; Margherita Milone; Duygu Selcen; Xin-Ming Shen; Andrew G Engel; Teerin Liewluck
Journal:  Neurology       Date:  2018-10-05       Impact factor: 9.910

4.  Intragenic DOK7 deletion detected by whole-genome sequencing in congenital myasthenic syndromes.

Authors:  Yoshiteru Azuma; Ana Töpf; Teresinha Evangelista; Paulo José Lorenzoni; Andreas Roos; Pedro Viana; Hidehito Inagaki; Hiroki Kurahashi; Hanns Lochmüller
Journal:  Neurol Genet       Date:  2017-05-03

Review 5.  Treating pediatric neuromuscular disorders: The future is now.

Authors:  James J Dowling; Hernan D Gonorazky; Ronald D Cohn; Craig Campbell
Journal:  Am J Med Genet A       Date:  2017-09-10       Impact factor: 2.802

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.